KA/EN
Register
Medicines reference
Search
Search
Product

Aristos P

Favourites

Marbofloxacin · Fatro S.p.A.

1 form: scored tablet. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Form Species Dose Frequency Georgia
20 mg, Scored tablet · Dog Dog 1 tablet per 10 kg
Exact Aristos P regimen: marbofloxacin 2 mg/kg PO once daily, one 20 mg tablet per 10 kg. Skin/soft tissue: at least 5 days, extend only by response up to 40 days. Urinary: at least 10 days, extend only by response up to 28 days. Respiratory: at least 7 days, extend only by response up to 21 days. Weigh accurately. The cross-score validates equal quarters: 5 mg per quarter, a 2.5 kg step at this regimen; do not infer crushing or smaller divisions. For staphylococcal pyoderma, current specialist guidance recommends at least 5.5 mg/kg; do not silently substitute that off-label regimen-review isolate-specific adequacy and select the appropriate authorised strategy.
 · once daily; duration is infection-site specific		 once daily; duration is infection-site specific Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: არისტოს პ 20 მგ
№ 292-11
Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration

Aristos P 20 mg, Scored tablet

marbofloxacin 20 mg, quadrisected tablet for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.5/10
Good
vetman assessment

Aristos P

20 mg, marbofloxacin 20 mg, quadrisected tablet for dogs
Assessed clinical scopeDog · Complete dog label: oral treatment of susceptible bacterial skin/soft-tissue, urinary including selected prostatic/epididymal, and respiratory infections when marbofloxacin is a justified reserve choice · By mouth
Care settingOutpatient reserve-antimicrobial treatment after diagnosis and accurate weighing, with susceptibility testing whenever possible and site-specific planned reassessment
vetman score 7.5/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 292-11 · Verified on 22 Oct 2026

A credible, accurately quarter-divisible oral reserve fluoroquinolone for selected susceptible adult-dog infections. Its good score is constrained by stewardship, long potential courses and the unresolved clinical adequacy of the 2 mg/kg label for staphylococcal pyoderma under current 5.5 mg/kg guidance.

Regulatory and scientific credibility9.0/10

The exact 20 mg Fatro product has current transparent EU/Czech and Georgian authorisations, Italian reference-product equivalence and current official GB/FDA same-active controls. Its generic legal basis is not a penalty, but independent exact-product outcome evidence is limited.

Clinical efficacy6.5/10

Marbofloxacin is established and the product has a clear 2 mg/kg regimen across susceptible skin, urinary and respiratory infections. Efficacy remains site/susceptibility dependent, and a material limitation is that current ISCAID pyoderma guidance recommends at least 5.5 mg/kg for Staphylococcus—well above this exact label—while fluoroquinolones remain reserve agents.

Safety and tolerability7.0/10

Correctly selected adult dogs generally tolerate labelled treatment; reported GI/thirst/activity changes are usually rare or very rare and mild. Juvenile cartilage injury, CNS/overdose effects, quinolone cross-resistance, reproductive prohibition and cation-reduced exposure remain clinically important hard boundaries.

Clinical practicality7.5/10

Once-daily home dosing and equal 5 mg quarters provide practical 2.5 kg steps. The broad site-specific courses can run 21-40 days, so adherence, quarter handling, repeated response review and stewardship are substantial; dogs below or between validated steps need a more suitable strength.

Full-course cost-effectiveness-

Current Georgian full-course price was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Scope boundary: this score covers the complete authorised susceptible bacterial dog scope. It does not cover cats, prophylaxis, non-bacterial disease, every organism without susceptibility, another strength or another jurisdiction's regimen.
  • Stewardship hard stop: marbofloxacin is an EMA AMEG Category B (Restrict) fluoroquinolone. Use only when an effective lower-category option is unsuitable, preferably after culture/susceptibility, and document the reason.
  • Pyoderma dose conflict: exact Aristos P is labelled 2 mg/kg/day, while ISCAID 2025 recommends at least 5.5 mg/kg for Staphylococcus spp. Do not silently increase this product; review isolate/site adequacy and select the appropriate authorised or explicitly justified strategy.
  • Exact dose: 2 mg/kg PO once daily, one 20 mg tablet/10 kg. Equal quarters provide 5 mg and a 2.5 kg step. Weigh accurately; do not invent eighths, crush-derived doses or transfer FDA Zeniquin's 2.75-5.5 mg/kg range.
  • Duration is site-specific, not automatic: skin at least 5 and up to 40 days; urinary at least 10 and up to 28 days; respiratory at least 7 and up to 21 days. Extend only after objective response and diagnosis/source-control review.
  • Do not use in growing dogs younger than the exact breed-size limit of 8-18 months or in sexually immature male dogs: fluoroquinolones can erode juvenile articular cartilage. Do not let apparent tolerance erase the contraindication.
  • Avoid in CNS dysfunction and use extreme caution with seizure risk. Stop and reassess ataxia, seizure, depression, aggression or marked hyperactivity; neurological overdose has no specific antidote and is treated symptomatically.
  • Do not use for confirmed/suspected quinolone resistance or strict anaerobic, yeast or fungal infection. Cross-resistance is extensive; treatment failure requires culture, source-control and diagnosis review—not blind dose escalation.
  • Exact-product pregnancy/lactation use is prohibited in the sourced label. Do not replace that restriction with a comparator brand's different benefit-risk wording or laboratory-species reassurance.
  • Oral aluminium, calcium, magnesium and iron can reduce marbofloxacin bioavailability. Concomitant theophylline can accumulate because fluoroquinolones reduce its clearance; review dose reduction and toxicity monitoring. Wash hands and seek medical advice after accidental ingestion.
Assessment sources
  1. EU SPC 20262026
  2. Aristos P GE register2026
  3. Aristos P IT equivalence2023
  4. Marbocyl P 20 VMD2026
  5. FDA 20192019
  6. EMA AMEG 20252025
  7. ISCAID 20252025
  8. ISCAID urinary 20192019
  9. ISCAID 20172017
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Marbofloxacin20 mg
Formulation Type
Scored tablet
Administration route
By mouth
Manufacturer
Fatro S.p.A. · Italy
Manufacturer (register)
Fatro S.p.A., Italy
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1206, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: არისტოს პ 20 მგ
№ 292-11
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ 96/057/18-C
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Prescription-only reserve fluoroquinolone. Exact label: 2 mg/kg PO once daily, one 20 mg tablet/10 kg. Skin/soft tissue 5-40 days, urinary 10-28 days and respiratory 7-21 days only according to diagnosis, susceptibility and response. Equal quarters provide 5 mg/2.5 kg steps. Current specialist guidance recommends at least 5.5 mg/kg for staphylococcal pyoderma; do not silently transfer that higher regimen—review whether the exact product/label is adequate or choose another authorised strategy.
DoseSpeciesWeightRouteFrequencySource
1 tablet per 10 kg
Exact Aristos P regimen: marbofloxacin 2 mg/kg PO once daily, one 20 mg tablet per 10 kg. Skin/soft tissue: at least 5 days, extend only by response up to 40 days. Urinary: at least 10 days, extend only by response up to 28 days. Respiratory: at least 7 days, extend only by response up to 21 days. Weigh accurately. The cross-score validates equal quarters: 5 mg per quarter, a 2.5 kg step at this regimen; do not infer crushing or smaller divisions. For staphylococcal pyoderma, current specialist guidance recommends at least 5.5 mg/kg; do not silently substitute that off-label regimen-review isolate-specific adequacy and select the appropriate authorised strategy.
 Dog Any weight By mouth once daily; duration is infection-site specific
EU SPC 2026
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Aristos P 20 mg tablets for dogs - Summary of Product Characteristics
EU Union Product Database, 2026

Known Contraindications

  • Critical
    Do not use in animals hypersensitive to fluoroquinolones or any product component. Do not use where quinolone resistance is confirmed; cross-resistance among fluoroquinolones is almost complete.
    Sources: VMD SPC · VMD · FDA
  • Critical (Dog)
    Age limits differ by product: one label prohibits use in dogs younger than 12 months and in slow-growing large breeds younger than 18 months; another uses 8 months for small/medium breeds, 12 months for large breeds, and 18 months for giant breeds. Fluoroquinolones can erode articular cartilage in growing dogs.
    Sources: VMD SPC · VMD · FDA
  • Warning
    Use with caution in dogs or cats with epilepsy because fluoroquinolones can cause neurological adverse effects. Overdose may cause acute neurological disturbances requiring symptomatic management.
    Sources: VMD SPC · VMD
  • Warning
    Safety in pregnant dogs and cats has not been established. Use only after a benefit-risk assessment. Studies in pregnant rats and rabbits found no adverse effects, but target-species studies are lacking; this means unassessed, not proven safe.
    Sources: VMD SPC · VMD
  • Warning
    Safety during lactation in dogs and cats has not been established. Use only after a benefit-risk assessment; the reviewed labels provide pregnancy data but no separate lactation statement.
    Sources: FDA

Known Drug Interactions

  • Major warning Marbofloxacin + Aminophylline
    Theophylline metabolism is inhibited by... enrofloxacin, and marbofloxacin
    Recommendation: Reduce the aminophylline dose during concomitant use. Signs of toxicity include vomiting, excitation, tachyarrhythmia, and seizures.
    Sources: MSD Vet Manual
  • Major warning Marbofloxacin + Sucralfate
    Sucralfate, antacids, and mineral supplements containing iron, aluminium, calcium, magnesium, zinc, or other divalent or trivalent cations can reduce quinolone absorption and bioavailability. The magnitude is drug-specific; marbofloxacin is covered by a direct product warning.
    Recommendation: Avoid concurrent oral administration. If both medicines are necessary, separate sucralfate or the cation-containing product from the quinolone by at least 2 hours and monitor clinical response.
    Sources: VMD SPC · VMD · FDA · ACVIM · JVIM
  • Major warning Marbofloxacin + Theophylline
    Fluoroquinolones can increase serum theophylline concentrations. When marbofloxacin and theophylline are used together, monitor theophylline closely because its therapeutic range is narrow and toxicity may occur.
    Recommendation: If concomitant use is necessary, monitor serum theophylline and be prepared to reduce its dose. Alternatively, choose another antibiotic.
    Sources: VMD SPC · VMD

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (59 more) Hide additional products

Same therapeutic group 59

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗